1. Home
  2. ANET vs NVO Comparison

ANET vs NVO Comparison

Compare ANET & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arista Networks Inc.

ANET

Arista Networks Inc.

SELL

Current Price

$177.48

Market Cap

238.0B

ML Signal

SELL

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

SELL

Current Price

$38.70

Market Cap

199.4B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ANET
NVO
Founded
2004
1923
Country
United States
Denmark
Employees
N/A
N/A
Industry
Computer Communications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
238.0B
199.4B
IPO Year
2014
2001

Fundamental Metrics

Financial Performance
Metric
ANET
NVO
Price
$177.48
$38.70
Analyst Decision
Strong Buy
Hold
Analyst Count
32
14
Target Price
★ $245.14
$45.68
AVG Volume (30 Days)
4.8M
★ 11.9M
Earning Date
11-03-2026
11-04-2026
Dividend Yield
N/A
★ 3.27%
EPS Growth
★ 23.32
N/A
EPS
★ 1.75
N/A
Revenue
★ $9,005,700,000.00
N/A
Revenue This Year
$40.81
N/A
Revenue Next Year
$29.03
$1.39
P/E Ratio
$105.70
★ $13.60
Revenue Growth
★ 28.60
N/A
52 Week Low
$114.52
$35.12
52 Week High
$217.41
$64.16

Technical Indicators

Market Signals
Indicator
ANET
NVO
Relative Strength Index (RSI) 32.81 40.92
Support Level $157.74 $38.02
Resistance Level $189.82 $39.58
Average True Range (ATR) 6.50 0.64
MACD -3.69 0.35
Stochastic Oscillator 4.23 67.40

Price Performance

Historical Comparison
ANET
NVO

About ANET Arista Networks Inc.

Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three-fourths of its sales from North America.

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: